MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-16-2026
Zomedica Corp. EPS Ratio 2011-2026 | ZOM
EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.
The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.
Calculated as:
EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares[1]
EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.
A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.
EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.
Annual EPS Ratio Zomedica Corp.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.08 | -0.05 | -0.035 | -0.017 | - | -0.05 | -0.19 | -0.18 | -0.09 | -0.07 | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -0.017 | -0.19 | -0.0847 |
Quarterly EPS Ratio Zomedica Corp.
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.01 | -0.01 | -0.07 | - | -0.01 | -0.02 | -0.01 | - | -0.001 | -0.005 | -0.007 | - | -0.005 | -0.005 | -0.004 | - | -0.006 | -0.005 | -0.04 | - | -0.01 | -0.02 | -0.02 | - | -0.03 | -0.02 | -0.12 | - | -0.02 | -0.04 | -0.02 | - | -0.02 | -0.02 | -0.02 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -0.001 | -0.12 | -0.021 |
References
- Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.
EPS Ratio of other stocks in the Drug manufacturers industry
| Issuer | EPS Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AcelRx Pharmaceuticals
ACRX
|
-0.34 | - | 7.5 % | $ 6.35 M |  USA |
 |
Aerie Pharmaceuticals
AERI
|
-1.61 | - | - | $ 754 M | USA |
 |
Agile Therapeutics
AGRX
|
-6.71 | - | 10.11 % | $ 58.2 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-0.18 | - | 0.86 % | $ 117 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
-0.14 | $ 4.06 | 4.1 % | $ 57.1 M | USA |
 |
Catalent
CTLT
|
-5.76 | - | - | $ 11.5 B | USA |
 |
Alimera Sciences
ALIM
|
-0.84 | - | - | $ 142 M | USA |
 |
Athenex
ATNX
|
-15.8 | - | -23.39 % | $ 1.76 M | USA |
 |
DURECT Corporation
DRRX
|
-1.05 | - | - | $ 50.1 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
2.76 | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
-10.4 | - | - | $ 28.9 M |  Irlanda |
 |
Avadel Pharmaceuticals plc
AVDL
|
-0.51 | - | - | $ 2.06 B |  France |
 |
Evoke Pharma
EVOK
|
-2.33 | - | - | $ 36.6 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-9.66 | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
-0.89 | - | 2.45 % | $ 38.1 M |  Canada |
 |
Bausch Health Companies
BHC
|
-1.62 | $ 5.63 | 1.53 % | $ 2.05 B | Canada |
 |
Jupiter Wellness
JUPW
|
-17 | - | - | $ 33.6 M | USA |
 |
Canopy Growth Corporation
CGC
|
-5.56 | $ 1.19 | -2.87 % | $ 128 M | Canada |
 |
Harrow Health
HROW
|
-0.14 | $ 39.7 | 2.45 % | $ 1.46 B | USA |
 |
Lannett Company
LCI
|
-5.74 | - | 1.15 % | $ 7.11 M | USA |
 |
OrganiGram Holdings
OGI
|
-0.51 | $ 1.45 | 0.7 % | $ 402 M | Canada |
 |
Organogenesis Holdings
ORGO
|
-0.01 | $ 2.35 | 0.86 % | $ 309 M | USA |
 |
Evolus
EOLS
|
-0.8 | $ 5.3 | -0.19 % | $ 342 M | USA |
 |
Sundial Growers
SNDL
|
-1.1 | $ 1.51 | -1.31 % | $ 3.37 M | Canada |
 |
Emergent BioSolutions
EBS
|
-14.8 | $ 8.03 | -0.74 % | $ 411 M | USA |
 |
Pacira BioSciences
PCRX
|
-2.15 | $ 24.51 | -3.35 % | $ 1.13 B | USA |
 |
Neoleukin Therapeutics
NLTX
|
-4.24 | - | - | $ 193 M | Canada |
 |
ProPhase Labs
PRPH
|
1.17 | - | - | $ 5.07 M | USA |
 |
cbdMD
YCBD
|
-1.79 | $ 1.01 | - | $ 4.36 M | USA |
 |
Radius Health
RDUS
|
-1.49 | - | - | $ 1.42 B | USA |
 |
Assertio Holdings
ASRT
|
-4.74 | $ 18.04 | 0.11 % | $ 116 M | USA |
 |
PetIQ
PETQ
|
0.07 | - | 1.64 % | $ 400 M | USA |
 |
Solid Biosciences
SLDB
|
-1.99 | $ 7.92 | -3.65 % | $ 693 M | USA |
 |
Relmada Therapeutics
RLMD
|
-1.45 | $ 7.21 | -0.55 % | $ 285 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
-2.79 | $ 1.14 | -36.67 % | $ 1.41 M | USA |
 |
Recro Pharma
REPH
|
-0.14 | - | -4.76 % | $ 65.3 M | USA |
 |
Tilray
TLRY
|
-2.35 | $ 6.75 | -2.74 % | $ 4.17 B | Canada |
 |
OptiNose
OPTN
|
-0.32 | - | - | $ 1.08 B | USA |
 |
SCYNEXIS
SCYX
|
-0.17 | $ 1.02 | -2.86 % | $ 50.9 M | USA |
 |
PLx Pharma
PLXP
|
-2.06 | - | -27.8 % | $ 2.56 M | USA |
 |
Veru
VERU
|
-0.28 | $ 2.32 | 0.43 % | $ 313 M | USA |
 |
Viatris
VTRS
|
0.05 | $ 14.59 | -1.08 % | $ 17.5 B | USA |
 |
Aurora Cannabis
ACB
|
-4.1 | $ 3.39 | 3.35 % | $ 86.3 M | Canada |
 |
Zynerba Pharmaceuticals
ZYNE
|
-0.82 | - | - | $ 55.5 M | USA |
 |
Rockwell Medical
RMTI
|
-0.15 | $ 0.87 | 1.99 % | $ 31.3 M | USA |
 |
Tricida
TCDA
|
-3.44 | - | - | $ 3.25 M | USA |
 |
China Pharma Holdings
CPHI
|
-0.74 | $ 0.61 | 1.65 % | $ 2.62 M |  China |
 |
TherapeuticsMD
TXMD
|
-0.05 | $ 2.19 | 0.46 % | $ 25.3 M | USA |